Insulet Corp. logo
PODDInsulet Corp.

Average Profit Margin

Profit Margin

The latest reported profit margin is 11.96% as of Tuesday, March 31, 2026, shown against its trailing averages.

PODD Profit Margin

PODD Average Profit Margin

PODD Profit Margin Averages

PROFIT MARGIN LATEST REPORTED

11.96%

PROFIT MARGIN TTM

9.40%

PROFIT MARGIN 3Y

11.30%

PROFIT MARGIN 5Y

9.02%

PROFIT MARGIN 10Y

2.38%

PROFIT MARGIN 15Y

-4.94%

PROFIT MARGIN 20Y

-10.29%

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy